Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Stock Information for Adaptimmune Therapeutics plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adaptimmune Therapeutics plc

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025
Processa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering
Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate
Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025
Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting
Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.